TRexBio is developing technology for functional manipulation of immune cells. The immune system plays a significant role in the development of disease. This includes regulatory T cells (Tregs) that mediate tissue healing. Using their Deep Biology platform, TRexBio is mapping Treg behavior in human tissue to dysregulation in disease. This enables TRexBio to identify novel therapeutics for the treatment of immune-mediated diseases. Currently, TRexBio is advancing multiple large molecule therapeutic candidates with their lead program, TRB-051 in clinical stages.

TRexBio

Founded: 2018
Location: South SF, CA
Employee range: 11 - 50
Clinical stage: RD
Therapy area: Immune-mediated disease
Drug types: IMM
Lead product: TRB-051
Funding: $26M A Mar 2022; $57M A Jun 2021

Drug notes:

About:

Jobs: